trial

Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia

NCTId NCT04252131
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 92 (actual)
Sponsored by Calo Psychiatric Center
Primary completion 2019-10-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
92 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2018-05-17
Primary completion
2019-10-31
Eligibility
ALL · 21 Years · 65 Years

Interventions & indications

Drugs
cassia seed tablet

Sponsors

Calo Psychiatric CenterLead Sponsor

Investigators

1
For-Wey Lung, MD, ScDPrincipal Investigator

Sites

1 total
Pingtung City, Taiwan

Facts & assertions

4 sourced
Enrollment
92
Phase
PHASE1
Primary Completion Date
2019-10-31
Status
COMPLETED
relationships
The graph out of here
drug
cassia seed tablet
drug
lead_sponsor
Calo Psychiatric Center
company
indication
Schizophrenia
indication
Obesity
indication
Schizophrenia
indication
investigator
For-Wey Lung, MD, ScD
person